Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
View Patent ↗Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
1. A compound of the formula I
in which the meanings are
A, B, D, E independently of one another C(R5) or N,
where not more than two of the radicals A, B, D, E may have the meaning of N;
G, L, R, T, independently of one another ═C(R6)-, —C(R6)(R7)-, ═N—, —N(R8)- or O, where not more than two of the radicals G, L, R, T may have the meaning of ═N—, —N(R8)- or O;
with the proviso that A, B, D, E and G, L, R, T and the C atoms to which they are bonded do not simultaneously form phenyl;
M ═C—, —C(R9)- or N;
W O, S, CH(R10);
Y (C 2 -C 10 )-alkylene, where one or two CH 2 groups may be replaced by O, S, N(R10a), —CH═CH—, —CH(phenyl)- or CON(R10b);
R1 (C 1 -C 16 )-alkyl, (C 1 -C 2 )-haloalkyl, (C 6 -C 10 )-aryl, (C 3 -C 12 )-heteroaryl, (C 3 -C 12 )-heterocyclyl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heteroaryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heterocyclyl or (C 1 -C 6 )-alkylene-(C 3 -C 12 )-cycloalkyl,
where aryl, heteroaryl, heterocyclyl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R11)(R12), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , oxo, COOH, COO—(C 1 -C 6 )-alkyl, CON(R13)(R14), N(R15)CO(R16), N(R17)SO 2 (R18), CO(R19), (CR20R21) x -O(R22), O—CO—N(R23)(R24), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R25)(R26);
x 0, 1, 2, 3, 4, 5, 6;
R10a, R10b, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
R2 hydrogen, —CO—N(R3a)-R4, —CO—R4, —CO—O—R4, (C 3 -C 12 )-heteroaryl,
where heteroaryl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R27)(R28), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R29)(R30), N(R31)CO(R32), N(R33)SO 2 (R34), CO(R35), (CR36R37) x′ -O(R38), O—CO—N(R39)(R40), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R41)(R42),
x′ 0, 1, 2, 3, 4, 5, 6;
R3, R3a independently of one another hydrogen, (C 1 -C 6 )-alkyl, benzyl;
R4 hydrogen, (C 1 -C 16 )-alkyl, (C 1 -C 6 )-alkylen-OH, (C 6 -C 10 )-aryl, (C 3 -C 12 )-heteroaryl, —(C 3 -C 12 )-heterocyclyl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heteroaryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heterocyclyl or (C 1 -C 6 )-alkylene-(C 3 -C 12 )-cycloalkyl,
where aryl, heteroaryl, heterocyclyl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R43)(R44), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO 2 (R50), CO(R51), (CR52R53) x″ -O(R54), O—CO—N(R55)(R56), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R57)(R58),
x″ 0, 1, 2, 3, 4, 5, 6;
R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41,
R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
R5 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, (C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R59)(R60), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R61)(R62), N(R63)CO(R64), N(R65)SO 2 (R66), CO(R67), (CR68R69) x″ -O(R70), O—CO—N(R71)(R72), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R73)(R74);
x′″ 0, 1, 2, 3, 4, 5, 6;
R6, R7 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R75)(R76), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , oxo, COOH, COO—(C 1 -C 6 )-alkyl, CON(R77)(R78), N(R79)CO(R80), N(R81)SO 2 (R82), CO(R83), (CR84R85) x″″ -O(R86), O—CO—N(R87)(R88), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R89)(R90);
R8 independently of one another hydrogen, (C 1 -C 6 )-alkyl, CF 3 , CN, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, SO 2 —CH 3 , SO 2 —NH 2 , COO—(C 1 -C 6 )-alkyl, CON(R77)(R78), CO(R83), (CR84R85) x″″ -O(R86);
x″″ 0, 1, 2, 3, 4, 5, 6;
R9, R10 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, OH, CF 3 , (C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, (CR91R92) y -O(R93);
y 0, 1, 2, 3, 4, 5, 6;
R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73,
R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
and the pharmaceutically acceptable salts thereof.
2. A compound of the formula I as claimed in claim 1 , in which the meanings are
A, B, D, E form with the atoms to which they are bonded a ring system selected from the group:
G, L, R, T and M form a ring system selected from the group:
with the proviso that A, B, D, E and G, L, R, T and the C atoms to which they are bonded do not simultaneously form phenyl;
W O, S, CH(R10);
Y C(R11a)(R11b)C(R11c)(R11d)C(R11e)(R11f)-, O—C(R11a)(R11b)C(R11c)(R11d)-, —S—C(R11a)(R11b)C(R11c)(R11d)-, —CH═CH—C(R11a)(R11b)-;
R1 (C 1 -C 16 )-alkyl, (C 1 -C 2 )-haloalkyl, (C 6 -C 10 )-aryl, (C 3 -C 12 )-heteroaryl, (C 3 -C 12 )-heterocyclyl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heteroaryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heterocyclyl or (C 1 -C 6 )-alkylene-(C 3 -C 12 )-cycloalkyl,
where aryl, heteroaryl, heterocyclyl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R11)(R12), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , oxo, COOH, COO—(C 1 -C 6 )-alkyl, CON(R13)(R14), N(R15)CO(R16), N(R17)SO 2 (R18), CO(R19), (CR20R21) x -O(R22), O—CO—N(R23)(R24), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R25)(R26);
x 0, 1, 2, 3, 4, 5, 6;
R10a, R10b, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
R11a, R11b, R11c, R11d, R11e, R11f
independently of one another hydrogen, (C 1 -C 3 )-alkyl, phenyl;
R2 CO—N(R3a)-R4, —CO—R4, —CO—O—R4,
R3, R3a independently of one another hydrogen, (C 1 -C 6 )-alkyl, benzyl;
R4 hydrogen, (C 1 -C 12 )-alkyl, (C 1 -C 6 )-alkylene-OH, phenyl (C 3 -C 12 )-heteroaryl, (C 3 -C 12 )-heterocyclyl, (C 3 -C 12 )-cycloalkyl, (C 1 -C 6 )-alkylene-(C 6 -C 10 )-aryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heteroaryl, (C 1 -C 6 )-alkylene-(C 3 -C 12 )-heterocyclyl or (C 1 -C 6 )-alkylene-(C 3 -C 12 )-cycloalkyl,
where aryl, heteroaryl, heterocyclyl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, O—(C 3 -C 8 )-cycloalkyl, (C 2 -C 6 )-alkynyl, N(R43)(R44), SO 2 —CH 3 , SO 2 —NH 2 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R45)(R46), N(R47)CO(R48), N(R49)SO 2 (R50), CO(R51), (CR52R53) x″ -O(R54), O—CO—N(R55)(R56), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R57)(R58);
x″ 0, 1, 2, 3;
R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58
independently of one another, hydrogen, (C 1 -C 6 )-alkyl;
R5 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, (C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R59)(R60), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , COOH, COO—(C 1 -C 6 )-alkyl, CON(R61)(R62), N(R63)CO(R64), N(R65)SO 2 (R66), CO(R67), (CR68R69) x″ -O(R70), O—CO—N(R71)(R72), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R73)(R74);
x′″ 0, 1, 2, 3, 4, 5, 6;
R6, R7 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R75)(R76), SO 2 —CH 3 , SO 2 —NH 2 , SF 5 , oxo, COOH, COO—(C 1 -C 6 )-alkyl, CON(R77)(R78), N(R79)CO(R80), N(R81)SO 2 (R82), CO(R83), (CR84R85) x″″ -O(R86), O—CO—N(R87)(R88), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—N(R89)(R90);
x″″0, 1, 2, 3, 4, 5, 6;
R10 hydrogen, (C 1 -C 6 )-alkyl, F, OH, CF 3 ;
R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
and the pharmaceutically acceptable salts thereof.
3. A compound of the formula I as claimed in claim 1 or 2 , in which the meanings are
A, B, D, E form with the atoms to which they are bonded a ring system selected from the group:
G, L, R, T and M form a ring system selected from the group:
with the proviso that A, B, D, E and G, L, R, T and the C atoms to which they are bonded do not simultaneously form phenyl;
W O, CHOH, CH 2 ;
Y C(R11a)(R11b)C(R11c)(R11d)C(R11e)(R11f)-, O—C(R11a)(R11b)C(R11c)(R11d)-, —S—C(R11a)(R11b)C(R11c)(R11d)-, —CH═CH—C(R11a)(R11b)-;
R1 (C 1 -C 8 )-alkyl, CF 3 , phenyl, (C 3 -C 8 )-heteroaryl, (C 3 -C 8 )-heterocyclyl, (C 3 -C 8 )-cycloalkyl, —CH 2 -phenyl, —CH 2 —(C 3 -C 8 )-heteroaryl, —CH 2 —(C 3 -C 8 )-heterocyclyl or —CH 2 —(C 3 -C 8 )-cycloalkyl,
where aryl, heteroaryl, heterocyclyl or cycloalkyl may be substituted one or more times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, S—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, N(R11)(R12), SO 2 —CH 3 , SO 2 —NH 2 , oxo, COOH, COO—(C 1 -C 6 )-alkyl, CON(R13)(R14), N(R15)CO(R16), N(R17)SO 2 (R18), CO(R19), (CR20R21) x -O(R22), O—CO—N(R23)(R24), O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl;
x 0, 1, 2, 3;
R11a, R11b, R11, R11d, R11e, R11f
independently of one another hydrogen, methyl, isopropyl, phenyl;
R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
R2 —CO—R4, —CO—O—R4;
R3 hydrogen, (C 1 -C 6 )-alkyl;
R4 hydrogen, methyl, benzyl, cyclopropyl, CH 2 OH, NH 2 ;
R5 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , N(R59)(R60), COO—(C 1 -C 6 )-alkyl, CON(R61)(R62), N(R63)CO(R64), CO(R67), (CR68R69) x′″ -O(R70);
x′″ 0, 1, 2, 3, 4, 5, 6;
R6, R7 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , O—(C 1 -C 6 )-alkyl, O—(C 1 -C 4 )-alkoxy-(C 1 -C 4 )-alkyl, N(R75) (R76), COO—(C 1 -C 6 )-alkyl, CON(R77)(R78), CO(R83), (CR84R85) x″″ -O(R86);
x″″ 0, 1, 2, 3, 4, 5, 6;
R59, R60, R61, R62, R63, R64, R67, R68, R69, R70, R75, R76, R77, R78, R83, R84, R85, R86
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
and the pharmaceutically acceptable salts thereof.
4. A compound of the formula I as claimed in claim 1 , 2 or 3 , in which the meanings are
A, B, D, E form with the atoms to which they are bonded a ring system selected from the group:
G, L, R, T and M form a ring system selected from the group:
with the proviso that A, B, D, E and G, L, R, T and the C atoms to which they are bonded do not simultaneously form phenyl;
W O, CHOH, CH 2 ;
Y C(R11a)(R11b)C(R11c)(R11d)C(R11e)(R11f)-, O—C(R11a)(R11b)C(R11c)(R11d)-, —S—C(R11a)(R11b)C(R11c)(R11d)-, —CH═CH—C(R11a)(R11b)-;
R1 (C 3 -C 8 )-alkyl, CF 3 , phenyl, pyridyl, isoxazolyl, pyrrolidinyl, cyclopentyl, tetrahydrofuranyl, —CH 2 -phenyl, —CH 2 -isoxazolyl, —CH 2 -pyrrolidinyl, —CH 2-cyclobutyl, —CH 2 -cyclopropyl or —CH 2 -cyclopentyl;
where each of the rings may be substituted once or twice by F, Cl, Br, I, OH, CF 3 , O—(C 1 -C 6 )-alkyl (C 1 -C 6 )-alkyl, (C 2 -C 4 )-haloalkyl, O—(C 2 -C 4 )-haloalkyl, N(R11)(R12), CO(R19), (CR20R21) x -O(R22), O—CO—N(R23)(R24);
x 0, 1, 2, 3;
R11a, R11b, R11, R11d, R11e, R11f
independently of one another hydrogen, methyl, isopropyl, phenyl;
R11, R12, R19, R20, R21, R22, R23, R24
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
R2 —CO—R4, —CO—O—R4;
R3 hydrogen, (C 1 -C 6 )-alkyl;
R4 hydrogen, methyl, benzyl, cyclopropyl, CH 2 OH, NH 2 ;
R5 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , O—(C 1 -C 6 )-alkyl, N(R59)(R60), COO—(C 1 -C 6 )-alkyl, CO(R67);
R6, R7 independently of one another hydrogen, (C 1 -C 6 )-alkyl, F, Cl, Br, I, OH, CF 3 , O—(C 1 -C 6 )-alkyl, N(R75)(R76), COO—(C 1 -C 6 )-alkyl, CO(R83);
R59, R60, R67, R75, R76, R83
independently of one another hydrogen, (C 1 -C 6 )-alkyl;
and the pharmaceutically acceptable salts thereof.
5. A compound of the formula I as claimed in claims 1 to 4 , in which
Y is —CH 2 —CH 2 —CH(CH 3 )—, —O—CH 2 —CH(CH 3 )— or —CH═CH—CH(CH 3 )—.
6. A compound of the formula I as claimed in claim 1 , 2 or 3 , in which
W is O.
7. A compound of the formula Ic
in which the symbols R1, Y, R2, R3 have the meanings mentioned in claims 1 to 4 , and the pharmaceutically acceptable salts thereof.
8. A compound of the formula Id
in which the symbols R1, Y, R2, R3 have the meanings mentioned in claims 1 to 4 , and the pharmaceutically acceptable salts thereof.
9. A compound of the formula Ia
in which the symbols R1, Y, R2, R3 have the meanings mentioned in claims 1 to 4 , and the pharmaceutically acceptable salts thereof.
10. A compound of the formula Ib
in which the symbols R1, Y, R2, R3 have the meanings mentioned in claims 1 to 4 , and the pharmaceutically acceptable salts thereof.
11. A compound of the formula I as claimed in claims 1 to 10 , in which
R2 is CO—CH 3 ;
R3 is hydrogen;
and the pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising the compound of claim 1 .
13. The pharmaceutical composition according to claim 12 , further comprising one or more active ingredients.
14. The pharmaceutical composition according to claim 13 , wherein said one or more active ingredients comprises one or more antidiabetics.
15. The pharmaceutical composition according to claim 13 , wherein said one or more active ingredients comprises one or more lipid modulators.
16. The pharmaceutical composition according to claim 13 , wherein said one or more active ingredients comprises one or more antiobesity agents.
17. A method of treating diabetes mellitus in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12 .
18. A method of treating obesity in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12 .
19. A process for the manufacture of a medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 11 , which comprises mixing the active ingredient with a pharmaceutically suitable carrier and converting this mixture into a form suitable for administration.